Insulin Lispro Market, By Product Type of Insulin Lispro, By Indication, By Age Group, By Drug Class (Humalog, Admelog and Other brands), By Distribution Channel, By Geography

Description

The global insulin lispro market size is estimated to be valued at US$ 7.32 Bn in 2023, and is projected to reach US$ 11.15 Bn by 2030 at a CAGR of 6.2% from 2023 to 2030.

Report Coverage		Report Details
Base Year:	2022	Market Size in 2023:	US$ 7.32 Bn
Historical Data for:	2018 to 2021	Forecast Period:	2023 - 2030
Forecast Period 2023 to 2030 CAGR:	6.20%	2030 Value Projection:	US$ 11.15 Bn

Figure 1. Global Insulin Lispro Market Share (%), By Region, 2023

Insulin lispro is used to treat type 1 diabetes (a condition in which the body does not produce insulin and cannot control the amount of sugar in the blood) in people who need insulin therapy. It is always used with another type of insulin, unless it is being used with an external insulin pump. Insulin lispro injection products are also used to improve glycemic control in adults with type 2 diabetes who do not respond well to oral medications alone. Insulin lispro is an analog insulin that differs from human insulin with a change in the sequence of two amino acids, proline at B-28 and lysine at B-29. This change prevents insulin from forming dimers and hexamers, which have lower activity than monomeric insulin. Insulin lispro is rapidly absorbed following subcutaneous administration, reaching peak levels within 2-4 hours and remaining effective for 18-30 hours.

Market Dynamics:

The global insulin lispro market has grown significantly in recent years, primarily due to an increase in the number of people living with diabetes and technological advancements in the field of insulin delivery devices. This growth is further expected to be supported by factors such as increasing government initiatives to improve healthcare and rising patient demand for insulin, as well as favorable medical reimbursement policies in developed countries. Changing lifestyles, such as an increased adoption of sedentary habits and unhealthy diets, have resulted in an increased number of people developing diabetes globally. As per the International Diabetes Federation, approximately 537 Mn adults were living with diabetes in 2021, and this number is expected to rise to 643 Mn by 2030 and 784 Mn by 2045. The increasing obesity rates and sedentary lifestyles have significantly contributed to this rise in diabetes cases. However, the high costs of insulin analogs and the availability of biosimilar alternatives remain a challenge for market growth. On the positive side, favorable government initiatives and improved access to healthcare services in developing nations present lucrative opportunities for players operating in this market. Developments in analog insulin delivery devices and formulations will also likely shape the future dynamics.

Key features of the study:

This report provides in-depth analysis of the global insulin lispro market, and provides market size (US$ Bn) and compound annual growth rate (CAGR%) for the forecast period (2023-2030), considering 2022 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global insulin lispro market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Eli Lilly and Company, Sanofi, Novo Nordisk A/S, Merck & Co., Inc., Pfizer Inc., Hoffmann-La Roche Ltd., AstraZeneca PLC, Johnson & Johnson Services, Inc., Biocon Limited, Mylan N.V., Boehringer Ingelheim, International GmbH, Wockhardt Ltd., Lupin Pharmaceuticals, Inc., Bioton S.A., Gan & Lee Pharmaceuticals and Ypsomed AG
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global insulin lispro market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global insulin lispro market

Detailed Segmentation:

By Product Type
- Insulin Lipro pre-filled pen
- Insulin lispro solution vials
- Insulin lispro solution cartridge
By Indication
- Type 1 Diabetes
- Type 2 Diabetes
- Gestational Diabetes
- Others
By Age Group
- Pediatric Patients
- Adult Patients
- Geriatric Patients
By Drug Class
- Humalog (Eli Lilly and Company)
- Admelog (Sanofi)
- Other brands
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Company Profiles
- Eli Lilly and Company
- Sanofi
- Novo Nordisk A/S
- Merck & Co., Inc.
- Pfizer Inc.
- F.Hoffmann-La Roche Ltd.
- AstraZeneca PLC
- Johnson & Johnson Services, Inc.
- Biocon Limited
- Mylan N.V.
- Boehringer Ingelheim International GmbH
- Wockhardt Ltd.
- Lupin Pharmaceuticals, Inc.
- Bioton S.A.
- Gan & Lee Pharmaceuticals
- Ypsomed AG

Product Code: CMI5719

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Insulin Lispro, By Product Type of Insulin Lispro
- Market Insulin Lispro, By Indication
- Market Insulin Lispro, By Age Group
- Market Insulin Lispro, By Drug Class
- Market Insulin Lispro, By Distribution Channel
- Market Insulin Lispro, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
Growing prevalence of diabetes
- Restrains
Decline in demand for insulin during Covid-19 pandemic
- Opportunities
Growing launch of new product
Impact Analysis
Key Highlights
Regulatory Scenario
Product launch/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario

4. Insulin Lispro Market - Impact of Coronavirus (COVID-19) Pandemic

COVID-19 Epidemiology
Supply Side and Demand Side Analysis
Economic Impact

5. Insulin Lispro Market , By Product Type of Insulin Lispro, 2018-2030, (US$ Bn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019 - 2030
- Segment Trends
Insulin Lipro pre-filled pen
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 -2030,(US$ Bn)
Insulin lispro solution vials
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 -2030,(US$ Bn)
Insulin lispro solution cartridge
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 -2030,(US$ Bn)

6. Insulin Lispro Market , By Indication, 2023-2030, (US$ Bn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019 - 2030
- Segment Trends
Type 1 Diabetes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 -2030,(US$ Bn)
Type 2 Diabetes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 -2030,(US$ Bn)
Gestational Diabetes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 -2030,(US$ Bn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 -2030,(US$ Bn)

7. Insulin Lispro Market , By Age Group, 2023-2030, (US$ Bn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019 - 2030
- Segment Trends
Paediatric Patients
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 -2030,(US$ Bn)
Adult Patients
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 -2030,(US$ Bn)
Geriatric Patients
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 -2030,(US$ Bn)

8. Insulin Lispro Market , By Drug Class, 2023-2030, (US$ Bn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019 - 2030
- Segment Trends
Humalog (Eli Lilly and Company)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 -2030,(US$ Bn)
Admelog (Sanofi)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 -2030,(US$ Bn)
Other Brands
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 -2030,(US$ Bn)

9. Insulin Lispro Market , By Distribution Channel, 2023-2030, (US$ Bn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019 - 2030
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 -2030,(US$ Bn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 -2030,(US$ Bn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 -2030,(US$ Bn)

10. Insulin Lispro Market , By Region, 2023-2030, (US$ Bn)

Introduction
- Market Share Analysis, By Country, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, For Country 2023 -2030
- Country Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type of Insulin Lispro, 2023-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2023-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2023-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2023-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2023-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country 2023-2030,(US$ Bn)
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type of Insulin Lispro, 2023-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2023-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2023-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2023-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2023-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country 2023-2030,(US$ Bn)
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type of Insulin Lispro, 2023-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2023-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2023-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2023-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2023-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country 2023-2030,(US$ Bn)
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type of Insulin Lispro, 2023-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2023-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2023-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2023-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2023-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country 2023-2030,(US$ Bn)
Middle East & Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type of Insulin Lispro, 2023-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2023-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2023-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2023-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2023-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country 2023-2030,(US$ Bn)

11. Competitive Landscape

Eli Lilly and Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Sanofi
Novo Nordisk A/S
Merck & Co., Inc.
Pfizer Inc.
Hoffmann-La Roche Ltd.
AstraZeneca PLC
Johnson & Johnson Services, Inc.
Biocon Limited
Mylan N.V.
Boehringer Ingelheim International GmbH
Wockhardt Ltd.
Lupin Pharmaceuticals, Inc.
Bioton S.A.
Gan & Lee Pharmaceuticals, Inc.
Ypsomed AG
Analyst Views

12. Section

Research Methodology
About us